NCT05213585

Brief Summary

Patients with Demodex infestation of the eyelids will have the sleeves from both eyes cleaned off with microblepharoexfoliation. Afterwards, one eye will be randomly selected for treatment with topical ivermectin 1% cream. The treatment will be repeated on that eye 2 weeks later. Afterwards, the patients will present monthly for photographs of the eyelashes. The photographs will be reviewed by an ophthalmologist outside of our institution who will be blind to which eye was treated and independently grade the amount of sleeves in each eye. The follow-up will be for 6 months after the second treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at P25-P50 for phase_1

Timeline
Completed

Started Aug 2021

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 24, 2021

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

January 20, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 28, 2022

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2022

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

January 28, 2022

Status Verified

January 1, 2022

Enrollment Period

9 months

First QC Date

January 20, 2022

Last Update Submit

January 20, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Comparative density of sleeves

    The density of sleeves will be clinically assessed and graded by the outcomes assessor

    Each patient will be followed for 6 months.

Secondary Outcomes (1)

  • Comparative assessment of tear osmolarity between treated and untreated eyes

    Each patient will be followed for 6 months

Study Arms (2)

Treated eyes

EXPERIMENTAL

All participants will have one eye randomly selected for treatment.

Drug: Ivermectin cream

Untreated eyes

NO INTERVENTION

No treatment will be given to the control eye.

Interventions

Topical application of ivermectin cream to eyelashes of treatment eye.

Treated eyes

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Helm Vision Group

Santa Clarita, California, 91355, United States

RECRUITING

Related Publications (1)

  • Choi Y, Eom Y, Yoon EG, Song JS, Kim IH, Kim HM. Efficacy of Topical Ivermectin 1% in the Treatment of Demodex Blepharitis. Cornea. 2022 Apr 1;41(4):427-434. doi: 10.1097/ICO.0000000000002802.

Central Study Contacts

Craig J Helm, MD

CONTACT

Valerie Garcia, COT

CONTACT

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The outcomes assessor is blind to which eye was treated. This is a single arm study in that only 1 treatment protocol is being tested in one eye and the contralateral eye is being used as the control. Masking of the outcomes assessor is being done to eliminate bias from the treating physician.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: The untreated eye will be observed in parallel with the contralateral treated eye.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician

Study Record Dates

First Submitted

January 20, 2022

First Posted

January 28, 2022

Study Start

August 24, 2021

Primary Completion

May 30, 2022

Study Completion

December 31, 2022

Last Updated

January 28, 2022

Record last verified: 2022-01

Data Sharing

IPD Sharing
Will not share

There is no current plan to share data with other researchers, unless requested.

Locations